Picture of Rohto Pharmaceutical logo

4527 — Rohto Pharmaceutical News Story

0.000.00%
jp flag iconLast trade - 00:00
HealthcareBalancedLarge CapHigh Flyer

Mitsui and Rohto to buy $594 mln Chinese medicines company Eu Yan Sang

SINGAPORE, April 4 (Reuters) - Japan's Mitsui & Co
 8031.T  said on Thursday it had teamed up with Rohto
Pharmaceutical Co  4527.T  to buy Eu Yan Sang International in a
deal valuing the Singapore-based traditional Chinese medicines
firm at S$800 million ($594 million).
    Mitsui said in a statement that a special purpose company
jointly owned by Mitsui and Rohto would acquire around 86% of Eu
Yan Sang from Righteous Crane Holding.
    Righteous Crane Holding is owned by a fund managed by Tower
Capital Asia, a unit of Temasek Holdings and founding family
members of Eu Yan Sang, according to a separate statement issued
by Tower Capital Asia on Thursday. 
    Following the deal, a takeover bid for the remaining 14% of
Eu Yan Sang will be made, while the founding family of Eu Yan
Sang will reinvest partially into the Misui-Rohto special
purpose company, Mitsui added.    
    Reuters reported in January that Mitsui and Hillhouse had
emerged as the final bidders vying for Eu Yan Sang. 
    Founded in 1879, Eu Yan Sang operates over 170 retail
outlets and 30 clinics in Singapore, Hong Kong, and Malaysia,
according to Mitsui's statement.
    Righteous Crane Holding took the company private from the
Singapore bourse in 2016. The deal valued Eu Yan Sang at about
$196 million at the time.
    Mitsui said it invested indirectly in Eu Yan Sang in
November 2022. The Japanese firm added that it had contributed
to the expansion of Eu Yan Sang's (EYS) business by helping to
boost the company's brand and supporting overseas expansion.
    "Through these activities, Mitsui reconfirmed EYS's strong
business potential and how Mitsui could contribute to its
business expansion," Mitsui said, adding this led to its
decision to re-invest in Eu Yan Sang with Rohto and the founding
family via the special purpose company. 
    The transaction is expected to close by June, according to
Tower Capital Asia's statement.
    Deutsche Bank  DBKGn.DE  and UBS  UBSG.S  are acting as
financial advisers to Eu Yan Sang, with WongPartnership as the
legal counsel, the statement showed.
    ($1 = 1.3467 Singapore dollars)

 (Reporting by Yantoultra Ngui#
Editing by Mark Potter)
 ((Yantoultra.Ngui@thomsonreuters.com;))

Recent news on Rohto Pharmaceutical

See all news